Abstract
Several new polyamine analogues have been developed for the treatment of human solid tumors. The phenotype-specific activity of some of these analogues has been associated with the superinduction of the rate-limiting enzyme in polyamine catabolism spermidine/spermine N1-acetyltransferase (SSAT). Using immunohistochemistry, we found a majority (64%) of human primary lung cancer explants to exhibit high expression of SSAT after treatment with 10 μM N1,N11-bis(ethyl)norspermine, an agent currently undergoing Phase II clinical trials against several important human solid tumors. The staining of SSAT was found specifically in the tumor tissue and not in the neighboring normal lung tissue. These results demonstrate the ability to detect induction of SSAT in clinical specimens and suggest the potential of this test as a prognostic indicator of drug response.
Original language | English (US) |
---|---|
Pages (from-to) | 1638-1641 |
Number of pages | 4 |
Journal | Clinical Cancer Research |
Volume | 5 |
Issue number | 7 |
State | Published - Jul 1999 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research